Neuren Pharmaceuticals Partners with Hope for HIE to Develop New HIE Treatment

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.

Neuren Pharmaceuticals has partnered with Hope for HIE to advance the development of NNZ-2591 for treating hypoxic-ischemic encephalopathy (HIE), a severe brain injury in newborns. This collaboration aims to address the critical unmet needs of the HIE community by focusing on both acute and chronic effects of the condition, potentially offering a new treatment paradigm beyond the currently approved hypothermia therapy. The partnership reflects a shared commitment to improving outcomes for children affected by HIE and underscores Neuren’s strategy of working with patient advocacy organizations to enhance its drug development programs.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is a company focused on developing new drug therapies for serious neurological disorders that emerge in early childhood and often have limited or no approved treatment options. One of their products, DAYBUE™ (trofinetide), is approved for the treatment of Rett syndrome, and they have licensed it to Acadia Pharmaceuticals Inc. for global development and commercialization. Their second drug candidate, NNZ-2591, is under development for multiple neurodevelopmental disorders, showing positive results in Phase 2 trials for conditions such as Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.

YTD Price Performance: 63.84%

Average Trading Volume: 541,933

Technical Sentiment Signal: Buy

Current Market Cap: A$2.59B

For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.